Market Place
Sourcing Support
First Participants Enrolled In Phase I Trial Of Nociceptin Agonist
22 Oct 2024 //
PR NEWSWIRE
Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
30 Sep 2024 //
PR NEWSWIRE
Grünenthal continues US growth push with $250M acquisition of Valinor Pharma
23 Jul 2024 //
FIERCE PHARMA
Grünenthal plants in South America will get $87M in upgrades
18 Jul 2024 //
FIERCE PHARMA
Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration
02 Aug 2023 //
PR NEWSWIRE
Grünenthal Announces Pricing of €300 Million Bond
19 Apr 2023 //
BUSINESSWIRE
Kyowa Kirin offloads mature drugs to Grünenthal in Europe
28 Nov 2022 //
FIERCEPHARMA
Grunenthal and Kyowa Announce Collaboration for Established Medicines Portfolio
25 Nov 2022 //
BUSINESSWIRE
Grünenthal closes deal to acquire testosterone therapy Nebido from Bayer
02 Nov 2022 //
PRNEWSWIRE
Grünenthal Is Said to Lead Race for Kyowa Kirin International
14 Oct 2022 //
FIRSTWORLDPHARMA
Grünenthal starts PIII trials for resiniferatoxin in osteoarthritis-related pain
18 Aug 2022 //
PRNEWSWIRE
Grünenthal to license osteoarthritis pain drug to Shionogi for up to > $500M
04 Aug 2022 //
PRNEWSWIRE
Bayer to sell testosterone drug for up to 500 mn euros
15 Jul 2022 //
ET HEALTH
Grünenthal, Uniklinik RWTH Aachen and University collaborate in pain research
07 Jul 2022 //
PRNEWSWIRE
Grünenthal donates 400.000€ and provides pain treatment medicine to Ukraine
07 Mar 2022 //
PRNEWSWIRE
Nationwide Survey by Averitas Reveals Painful Realities of Living with Diabetic Nerve Pain
14 May 2021 //
PRNESWIRE
Grünenthal successfully places first bond
06 May 2021 //
PRESS RELEASE
Grünenthal announces pricing of its first bond
23 Apr 2021 //
PRESS RELEASE
Grünenthal`s transformation: CEO Gabriel Baertschi about what`s ahead
12 Apr 2021 //
FIERCE PHARMA
Grünenthal acquires Mestex and its Ph-III-ready investigational medicine MTX-071
12 Apr 2021 //
PRESS RELEASE
Grünenthal is Recognized for its Strong Management of (ESG) Risks
07 Apr 2021 //
PRNEWSWIRE
Grünenthal’s first Environmental, Social and Governance Rating puts us ahead
07 Apr 2021 //
PRESS RELEASE
Grünenthal and Averitas Pharma announce initiation of Phase III study
30 Mar 2021 //
PRNEWSWIRE
Grünenthal Report 2019/20
19 Mar 2021 //
PRESS RELEASE
Gathering insights from patients with cancer-related neuropathic pain
18 Feb 2021 //
PRESS RELEASE
Initial results from Mesoblast’s Phase III trial MSB-DR003
16 Feb 2021 //
PRESS RELEASE
Grünenthal successfully extends its term loan bank facilities
12 Feb 2021 //
PRESS RELEASE
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™
09 Feb 2021 //
PRNEWSWIRE
Recall of Palexia® oral solution 20mg/ml and Palexia® 4 mg/ml oral solution
08 Feb 2021 //
PRESS RELEASE
Understanding patients and supporting healthcare professionals in Spain
04 Feb 2021 //
PRESS RELEASE
Statement on the recall of two batches of Anulette in Chile
01 Feb 2021 //
PRESS RELEASE
Grünenthal Colombia achieves top ranking for outstanding logistics
21 Jan 2021 //
PRESS RELEASE
New Head Global Communications at Grünenthal
12 Jan 2021 //
PRESS RELEASE
Peripheral NOP agonist addressing chronic peripheral neuropathic pain
16 Dec 2020 //
PRNEWSWIRE
The PARADIGM project – a game-changer for patient engagement in R&D
25 Nov 2020 //
PRESS RELEASE
Grünenthal’s response to Covid-19
28 Oct 2020 //
PRESS RELEASE
Grünenthal terminates license supply agreement for ZALVISO™
19 Oct 2020 //
PRESS RELEASE
Supply disruption for esomeprazole 40mg
18 Sep 2020 //
PSNC
Grünenthal closes a deal with Teva to market teriparatide
18 Sep 2020 //
BORN2INVEST
Scientists quit back pain campaign over links to opioid giant Grünenthal
30 Aug 2020 //
THETIMES
Growth for Grünenthal with new Qutenza indication
22 Jul 2020 //
THEPHARMALETTER
FDA approves non-opioid capsaicin pain patch for diabetic neuropathy
21 Jul 2020 //
HEALIO
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA®
21 Jul 2020 //
GRUNENTHAL
Grünenthal issues notice to the(EC)& the (EMA) to withdraw Zurampic® & Duzallo®
30 Jun 2020 //
PRESS RELEASE
Fabia Kehren communicates for Grünenthal
26 Jun 2020 //
PR JOURNAL
German federal parliament strengthens legal certainty for Thalidomide
24 Jun 2020 //
PRESS RELEASE
Grünenthal mit dem Qualitätssiegel „audit berufundfamilie“ für eine familien
16 Jun 2020 //
PRESS RELEASE
AcelRx to regain rights to Zalviso after partner says it would terminate deal
23 May 2020 //
SPGLOBAL
AcelRx Says Grünenthal Said It Is Exercising RightTo Terminate License Agreement
22 May 2020 //
REUTERS
New Boston R&D hub gives Grünenthal bigger US presence
06 May 2020 //
THEPHARMALETTER
Rheumatic disease and COVID-19: data from the COVID-19 Global Rheumatology
01 May 2020 //
THELANCET
Patent Owner`s Printed Publication Stance Riles PTAB Judge
24 Apr 2020 //
LAW360
Grünenthal invests in e-mobility at headquarters in Aachen
02 Apr 2020 //
PRESS RELEASE
Grünenthal GmbH v. Alkem Labs. Ltd.
28 Mar 2020 //
JDSUPRA
Grünenthal invests in e-mobility at headquarters in Aachen
04 Feb 2020 //
PRESS RELEASE
Grünenthal expands its network through Innovation Hub in Boston
29 Jan 2020 //
PRESS RELEASE
OTS: Grünenthal Group / Grünenthal erweitert sein Netzwerk mit einem
29 Jan 2020 //
ONVISTA
Grünenthal expands its network through Innovation Hub in Boston
29 Jan 2020 //
PRESS RELEASE
Collaborating to raise the standard of care for patients.
18 Dec 2019 //
PRESS RELEASE
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)
18 Dec 2019 //
PR NEWSWIRE
